Vi använder cookies på våra webbplatser för att de ska fungera som väntat och bidra till den bästa användarupplevelsen.Genom att fortsätta använda vår webbplats accepterar du användandet av cookies. Läs mer om cookies här.
The British In Vitro Diagnostics Association (BIVDA) has launched its new report examining the value of IVDs. It is estimated that 70 % of clinical decisions are made using IVDs.
Report covers challenges which IVD sector is facing but also emphasizes the unique position of in-vitro-diagnostics in offering improved patient outcomes. The future of healthcare is personalized medicine, which ensures the right person gets the right treatment at the right time.
Report is focusing three key themes:
These three key areas are supported by case studies, which cover wide range of topics including case study “Protecting patients from AMR consequences”. This study stresses that point-of-care testing can play a vital role in aiding the decision whether to prescribe antibiotics of not. Studies have found that C-reactive protein (CRP) point-of-care testing can reduce antibiotic prescribing by 41%, which could result in an estimated saving of £56 million per year in the UK.BIDVA report:https://www.bivda.co.uk/Portals/0/Documents/Policy%20and%20Media/The%20Value%20of%20IVDs%208pp%20web.pdfCase studies:https://www.bivda.co.uk/Portals/0/Documents/Policy%20and%20Media/The%20Value%20Story%20Case%20Studies%20web.pdf
©2013 - 2018 Orion Diagnostica Oy / Sverige, Svärdvägen 21, Box 85, 182 11 Danderyd, Tel 08-623 64 40